Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.

As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...

Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

Pfizer named Dr Chris Boshoff as CSO and president of R&D, effective 1st January 2025. Boshoff, previously Pfizer’s chief ...

Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate nipocalimab for the treatment of generalized myasthenia gravis (gMG). The ...

Novo Nordisk A/S, a leading global healthcare company, and Valo Health, Inc. announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 ...